4.6 Article

Estrogen receptor β: Potential target for therapy in adult granulosa cell tumors?

Journal

GYNECOLOGIC ONCOLOGY
Volume 150, Issue 1, Pages 158-165

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2018.05.013

Keywords

Ovary; ER beta; Estradiol; Hormonal therapy; Mitochondria; Personalized medicine

Ask authors/readers for more resources

Objective. Adult granulosa cell tumor (AGCT) is a rare form of sex-cord stromal ovarian tumors. Due to their origin, AGCTs secrete estrogens, and thus, estrogen receptor (ER)-mediated signaling has been considered as a possible target for therapy. The aim of the present study was to get insights into estrogen receptor status and activity in AGCTs, as a strategy to provide molecular support for personalized hormonal treatments. Methods. We evaluated by immunohistochemistry the expression of ER alpha, ER beta isoforms (i.e. ER beta 1, ER beta 2 and ER beta 5), progesterone and androgen receptor (PR, AR) in 20 untreated AGCTs and 12 unmatched recurrent lesions. Thereafter, we visualized by immunofluorescence, the subcellular distribution of cytoplasmic receptors, and by the proximity ligation assays (PLA) we characterized in situ their ability to interact with other proteins involved in the apoptotic cascade. Results. Primary AGCTs predominantly expressed ER beta isoforms, along with PR and AR, while only 30% of patients showed ER alpha expression. Recurrent tumors were associated with a decrease in AR levels. From mechanistic studies it emerges that ER beta 2, and to a lesser extent ER beta 1 and AR, are mitochondrial components in cancer cells and that ER beta 2 can act as a binding partner of proteins involved in the apoptotic cascade, in turn potentially inhibiting apoptosis. Conclusions. As in other endocrine tumors, ER beta may play a role in the pathogenesis of AGCT; it is crucial to understand estrogen receptor-mediated pathways before planning hormonal treatment strategies in AGCT. (C) 2018 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Acoustics

Using IOTA terminology to evaluate fetal ovarian cysts: analysis of 51 cysts over 10-year period

A. Romiti, F. Moro, L. Ricci, C. Codeca, F. Pozzati, M. Viggiano, R. Vicario, I. Fabietti, G. Scambia, P. Bagolan, A. C. Testa, L. Caforio

Summary: This retrospective study examined 51 fetal ovarian cysts in 48 fetuses and reclassified the cysts using IOTA terminology. The results showed that anechoic cysts and cysts with low-level content often resolved spontaneously, while cysts with ground-glass, hemorrhagic, mixed, or undefined content were frequently associated with postoperative necrosis.

ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2023)

Review Oncology

Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis

Marco Filetti, Pasquale Lombardi, Raffaele Giusti, Rosa Falcone, Florian Scotte, Diana Giannarelli, Antonella Carcagni, Valeria Altamura, Giovanni Scambia, Gennaro Daniele

Summary: This study provides an up-to-date estimate of the efficacy and safety of different combinations used for chemotherapy-induced nausea and vomiting. Overall, 3- or 4-drug regimens containing dexamethasone, 5-HT3 antagonists, mirtazapine or olanzapine showed the highest probability of being the most effective in terms of complete response. Regimens containing dexamethasone and 5-HT3 antagonist had the lowest probability of being the most effective in terms of complete, acute, and delayed response.

CANCER TREATMENT REVIEWS (2023)

Article Obstetrics & Gynecology

Sperm human papillomavirus infection and risk of idiopathic recurrent pregnancy loss: insights from a multicenter case-control study

Andrea Busnelli, Andrea Garolla, Chiara Tersigni, Vittorio Parodi, Annalisa Inversetti, Paolo Emanuele Levi-Setti, Giovanni Scambia, Nicoletta Di Simone

Summary: This study aimed to test the association between human papilloma virus (HPV) sperm infection and idiopathic recurrent pregnancy loss (RPL). The results showed that the prevalence of HPV DNA sperm infection was significantly higher in couples affected by RPL than in their fertile counterparts. Approximately 1 out of 5 males in the affected couples had HPV sperm infection.

FERTILITY AND STERILITY (2023)

Article Oncology

The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma

Camilla Di Dio, Giorgio Bogani, Violante Di Donato, Ilaria Cuccu, Ludovico Muzii, Lucia Musacchio, Giovanni Scambia, Domenica Lorusso

Summary: Endometrial cancer is a heterogeneous disease with specific genomic, molecular, and biological features. Immune checkpoint inhibitors and tyrosine kinase inhibitors have shown promising results in the treatment of advanced or recurrent endometrial cancer. The combination of pembrolizumab and lenvatinib has become the new standard second-line treatment, regardless of the MMR status. Further studies are exploring the use of immune checkpoint inhibitors and PARP inhibitors in combination therapy.

GYNECOLOGIC ONCOLOGY (2023)

Article Oncology

Transvaginal ultrasound-guided biopsy in patients with suspicious primary advanced tubo-ovarian carcinoma

Floriana Mascilini, Lorena Quagliozzi, Mariateresa Mirandola, Francesca Moro, Nicoletta D'Alessandris, Francesca De Felice, Antonia Carla Testa, Giovanni Scambia, Anna Fagotti

Summary: This study aimed to evaluate the accuracy of pathological diagnosis by transvaginal ultrasound-guided biopsy versus surgery in patients with suspicious primary advanced tubo-ovarian carcinoma. The results showed that ultrasound-guided biopsy is a feasible, safe, and accurate method to provide histological diagnosis in these patients.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)

Article Nutrition & Dietetics

Predictive and prognostic effect of computed tomography-derived body composition analysis during neoadjuvant chemotherapy for operable and locally advanced breast cancer

Ilaria Trestini, Alberto Caldart, Marco Cintoni, Isabella Sperduti, Alessandro Drudi, Gregorio Aluffi, Elena Fiorio, Veronica Parolin, Valentina Zambonin, Sara Zanelli, Daniela Tregnago, Alice Avancini, Sara Pilotto, Irene Aprili, Emanuela Zandona, Mirko D'Onofrio, Maria Cristina Mele, Antonio Gasbarrini, Giovanni Scambia, Giampaolo Tortora, Michele Milella, Emilio Bria, Luisa Carbognin

Summary: This study evaluated the changes in body composition during neoadjuvant chemotherapy and its association with pathologic complete response and survival outcome in patients treated for operable locally advanced breast cancer.

NUTRITION (2023)

Editorial Material Obstetrics & Gynecology

Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Amit Oza, Antonio Gonzalez-Martin, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, John McNamara, Elizabeth S. Lowe, Mei-Lin Ah-See, Kathleen N. Moore

Summary: Due to nonspecific symptoms and inadequate screening, ovarian cancer is often diagnosed at an advanced stage, resulting in low survival rates. The PARP inhibitor olaparib has shown significant benefits in newly diagnosed advanced ovarian cancer patients with a BRCA mutation. The SOLO1/GOG 3004 study found that olaparib treatment resulted in prolonged progression-free survival up to 2 years and showed potential overall survival benefits up to 7 years. However, further analysis is needed to confirm the statistical significance.

OBSTETRICAL & GYNECOLOGICAL SURVEY (2023)

Article Andrology

Sperm DNA fragmentation and idiopathic recurrent pregnancy loss: Results from a multicenter case-control study

Andrea Busnelli, Andrea Garolla, Elena Di Credico, Silvia D'Ippolito, Anna Maria Merola, Domenico Milardi, Alfredo Pontecorvi, Giovanni Scambia, Nicoletta Di Simone

Summary: This study found that sperm DNA fragmentation is significantly higher in men associated with idiopathic recurrent pregnancy loss, but not with infertility. These findings provide important evidence for the role of sperm DNA fragmentation in idiopathic recurrent pregnancy loss.

ANDROLOGY (2023)

Article Oncology

Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study

David Cibula, Huseyin Akilli, Jiri Jarkovsky, Luc van Lonkhuijzen, Giovanni Scambia, Mehmet Mutlu Meydanli, David Isla Ortiz, Henrik Falconer, Nadeem R. Abu-Rustum, Diego Odetto, Jaroslav Klat, Ricardo dos Reis, Ignacio Zapardiel, Giampaolo Di Martino, Jiri Presl, Rene Laky, Aldo Lopez, Vit Weinberger, Andreas Obermair, Rene Pareja, Renata Poncova, Constantijne Mom, Nicolo Bizzarri, Martina Borcinova, Koray Aslan, Rosa Angelica Salcedo Hernandez, Guus Fons, Klara Benesova, Lukas Dostalek, Ali Ayhan

Summary: This study investigated the survival benefit of adjuvant (chemo)radiation after radical surgery in intermediate-risk early-stage cervical cancer patients and found that adjuvant treatment did not significantly improve disease-free and overall survival rates.

GYNECOLOGIC ONCOLOGY (2023)

Article Oncology

Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial

Lucia Musacchio, Margherita Turinetto, Laura Arenare, Michele Bartoletti, Daniela Califano, Valentina Tuninetti, Claudia Marchetti, Gennaro Cormio, Vera Loizzi, Carmela Pisano, Vanda Salutari, Giorgio Valabrega, Domenico Priolo, Sabrina Chiara Cecere, Jole Ventriglia, Francesco Raspagliesi, Francesco Perrone, Anna Fagotti, Domenica Lorusso, Giovanni Scambia, Sandro Pignata

Summary: The study aimed to explore the efficacy of Bevacizumab (Bev) in the treatment of advanced low grade serous ovarian cancer (LGSOC) in both first-line and recurrent settings. The results showed that Bev combined with chemotherapy significantly improved progression-free survival (PFS) in LGSOC patients compared to chemotherapy alone, both in first-line and recurrent treatments. These findings suggest that Bev may be an effective treatment option for LGSOC.

GYNECOLOGIC ONCOLOGY (2023)

Review Biotechnology & Applied Microbiology

Dostarlimab: From preclinical investigation to drug approval and future directions

Carlo Maria Cicala, Lucia Musacchio, Giovanni Scambia, Domenica Lorusso

Summary: Immune checkpoint blockers (ICB) reverse the immunosuppressive phenotype of cancer cells, allowing the host immune system to generate an immune response against the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which inhibits T-cell proliferation and leads to exhaustion. Anti-PD-1/PD-L1 monoclonal antibodies are now the main treatment for advanced stage tumors. Dostarlimab, a novel IgG4 anti-PD-1 antibody, has shown remarkable results in certain types of cancer.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2023)

Article Cardiac & Cardiovascular Systems

GENERATOR HEART FAILURE DataMart: An integrated framework for heart failure research

Domenico D'Amario, Renzo Laborante, Agni Delvinioti, Jacopo Lenkowicz, Chiara Iacomini, Carlotta Masciocchi, Alice Luraschi, Andrea Damiani, Daniele Rodolico, Attilio Restivo, Giuseppe Ciliberti, Donato Antonio Paglianiti, Francesco Canonico, Stefano Patarnello, Alfredo Cesario, Vincenzo Valentini, Giovanni Scambia, Filippo Crea

Summary: This study developed an HF DataMart framework for managing data of heart failure patients. It includes a data repository and predictive models to support clinical decision-making and disease monitoring. By leveraging real-world data, this framework can improve healthcare services for heart failure patients.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2023)

Article Surgery

Ultrasound-guided endoscopy to improve accuracy of persistent urogenital sinus (PUGS) diagnosis in adult patient: A case report

Mariateresa Mirandola, Benedetta Gui, Angelica Naldini, Nazario Foschi, Viola Casula, Antonia Carla Testa, Giovanni Scambia, Ursula Catena

Summary: This article reports a case of persistent urogenital sinus (PUGS) in an adult female associated with complex Mullerian malformation. The condition was diagnosed through the integration of gynecological ultrasound and hysteroscopy performed by expert operators. Ultrasound guided endoscopy played a crucial role in achieving a dynamic one-stop diagnosis, avoiding delays and misdiagnosis caused by the separate application of different radiological and endoscopic techniques in preoperative assessment.

FRONTIERS IN SURGERY (2023)

Article Obstetrics & Gynecology

Diagnostic factors for recurrent pregnancy loss: an expanded workup

Carlo Ticconi, Elena Nicastri, Silvia D'Ippolito, Carlo Chiaramonte, Adalgisa Pietropolli, Giovanni Scambia, Nicoletta Di Simone

Summary: This study investigated the risk factors for recurrent pregnancy loss (RPL) in 843 women by using a patient-based approach. The study found several factors related to RPL, including genital infections, uterine anatomic defects, endocrine disorders, thrombophilias, autoimmune abnormalities, parental karyotype abnormalities, and clinical factors. The number of abnormalities found was correlated with an increased number of pregnancy losses. Age >= 35 years, MTHFR A1298C heterozygote mutation, and certain clinical factors showed different associations with RPL occurring 2 times versus >= 3 times. The diagnostic approach used in this study can be clinically useful and serve as a basis for future research.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2023)

Article Oncology

Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients

Rosa Falcone, Pasquale Lombardi, Marco Filetti, Alessandra Fabi, Valeria Altamura, Giovanni Scambia, Gennaro Daniele

Summary: This study investigated the molecular and clinical characteristics of 38 patients with advanced breast cancer, and found that 14% of patients benefited from targeted therapy based on molecular analysis, resulting in prolonged progression-free survival. However, the real benefit of these treatments still needs to be evaluated in larger cohorts.

CURRENT ONCOLOGY (2023)

Article Oncology

Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions

Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko

Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.

GYNECOLOGIC ONCOLOGY (2024)